Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — H1 2022 Earnings Presentation
36 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2022
Slide 1: 1H2022 Results Update
x 1H2022 Results Update
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
LIST OF FIGURES Corporate Overview 04 Indonesia Healthcare Market 18 Financial Update 32 Global Trend in Diagnostic Lab Company Highlight 05 19 Gross Profit and Net Income 33 Market Company History 06 Growth Strategy 20 COGS and OPEX 34 Investment Highlight 07 Leader in Next Gen Technology 21 Financ
Slide 4: Corporate Overview
1 CORPORATE OVERVIEW 4
Slide 5: Company Highlight
• More than 49 years IDR 1.04 Trillion experience in Clinical Lab Industry since 1973 1H2022 Revenue (-16.3% yoy; 3yrs CAGR +9.1%) • Has the most recognized Brand in Indonesia >1.4 Million • Largest private 1H2022 Visit (-16.0% yoy; 3yrs CAGR +5.1%) independent clinical lab chain by size of network
Slide 6: Strong Track Record in Clinical Laboratory Testing
Strong Track Record in Clinical Laboratory Testing • Establishment of Prodia Became the first Established professional Partnerships National Referral Lab, Established clinical laboratory management team with National the first Indonesian lab Prodia ChildLab in Indonesia to Scholarships given t
Slide 7: Investment Highlight
2 INVESTMENT HIGHLIGHT 7
Slide 8: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2019 & 2020) (Billion IDR) 3YRS CAGR 7.4% 39.2% 39.5% 4,874 3YRS CAGR 4,222 4,551 8.2% 26.9% 2019 27.8% 2020 1,600 1,744 1,873 33.9% 32.7% 2018 2019
Slide 9: Operational Track Record
Operational Track Record VISITS REVENUE CAGR CAGR 7.7% 14.3% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 6.1% CAGR 34.4% 9 2016 2017 201
Slide 10: Comprehensive Service Offering with Multiple Customer Segments
Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of clin
Slide 11: Scalable Hub and Spoke Business Model
Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Significant Surabaya, Medan, Makassar Economies of Scale Achieved “Hub and spoke” model offers scalable platform reducing Centralized information Prodia Clinical Labs, Prodia Referral with integrated IT turnaround time and cost Hospit
Slide 12: Strong Relationship with Medical Community
Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Screenin
Slide 13: One of the Largest Digital Healthcare Platform in Indonesia
One of the Largest Digital Healthcare Platform in Indonesia Walk-in Apps Doctor Referral Apps Prodia Mobile Prodia Mobile for Doctor More than 1.1 mio Launched in April 2022 downloaders • Online Referral • Online registration • Online Chat • Online Payment 244.6% Patient’s Growth • Online Results •
Slide 14: Experienced Senior Leadership and Management Team
Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 30 Experience 30 Experience Andi Gunawan Endang Kemal Imam Keri
Slide 15: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 16: Market Overview & Growth Strategy
3 MARKET OVERVIEW & GROWTH STRATEGY 16
Slide 17: Indonesia Economic Outlook
Indonesia Economic Outlook 4.7% – 5.4% Indonesia’s GDP Growth Projection for 2022 Indonesia’s economic recovery and improvement in 2022 will GDP Growth Projection 2022 be supported by the Indonesia World stability to control Indonesia’s Govt’ 4.9% - 5.4% N/A COVID-19 pandemic, World Bank 5.1% 2.9% r
Slide 18: Indonesia Healthcare Market
Indonesia Healthcare Market Indonesia Healthcare Market Indonesia Digital Healthcare Market (IDR Trillion) (IDR Trillion) 700.0 624.2 50.0 45.5 585.3 600.0 548.3 509.1 40.0 462.7 435.1 472.4 500.0 423.3 435.0 28.0 400.0 30.0 300.0 20.0 17.2 200.0 10.6 8.1 10.0 3.9 5.9 100.0 0.9 2.3 - - 2017 2018 201
Slide 19: Company's Growth Strategy
Company’s Growth Strategy Strengthen digital capabilities to Expand our presence and enable business growth grow our network of outlets in both physical and digital Develop data & analytics channel in Indonesia Near- capabilities to create business values A term Upgrade existing clinical Enhance int
Slide 20: Global Trend in Diagnostic Lab Market
Global Trend in Diagnostic Lab Market 1 2 3 4 Creating Digital Strategic Customer Centric Development of Ecosystem Partnership and Model testing technology Collaboration and AI Healthcare Platform B2B Business Expansion Digital Customer Journey Preventive Genomics Electronic Health Record Market Con
Slide 21: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 22: Our Response to Business Landscape
Our Response to Business Landscape • Upgrade Prodia Mobile • Wellness Package • Prodia Mobile for Doctor • Genomic Tests • ProdiaLink for External Referral • Ethos – HS platform • Prodia in Your Car Lab Market: Digital Service Development Product and Lab Testing Innovation New Players Coming • Added
Slide 23: Prodia Sustainable Action Plan
Prodia Sustainable Action Plan Prodia Sustainable Action Plan is an initiative and effort made by Prodia in order to achieve sustainable business growth so as to create added value for stakeholders including shareholders, customers, medical personnel, regulators, the communities and the environment.
Slide 24: Business Update
4 BUSINESS UPDATE 24
Slide 25: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Facilities • Safety, Quality & Cleanliness Product Innovation of Our Lab/Facilities/Staffs • Complete Testing from Routine to Esoteric • Prodia Mobile Test, Genomics Testing • Home/Office Serv
Slide 26: New Innovation & Enhancement
Customer Centric Model Prodia in your Car New Innovation & Enhancement Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist ProdiaLink • Clinical Nutritionist • Sport Medicine
Slide 27: Digital Transformation to Fulfill Customer Needs
Digital Transformation to Fulfill Customer Needs Prodia Mobile apps provides online registration/booking, online payment, online results, chat with doctors, and home service booking. > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3.3.0 – Updated in April 2022 27
Slide 28: Digital Diagnostic Partner for Doctors
Digital Diagnostic Partner for Doctors Prodia Mobile for Doctor apps assist doctors to create testing referral to all Prodia’s Lab Services, provides live chat and manage their patient’s online health report. Launched in April 2022 28
Slide 29: Outlet Development
Outlet Development 2016-2022 Outlet Development 2022 Outlet Development Target 1-2 20 259 283 292 287 267 259 254 Clinical Labs POC Outlets 5 7 4** 4** 4** 2 4** 11 14 14 12 9 9 7 128 122 1-2 1 118 130 108 98 95 Hospital Labs Specialty Clinic 129 136 143 147* 148* 148* 148* “Prodia not only focus to
Slide 30: Strategic Partnership to Support Health Tourism
Strategic Partnership to Support Health Tourism Partnership with IHH Healthcare Malaysia: • Prodia as preferred Lab Partner through 152 branches in Indonesia. • Optimizing management of patient to access advanced laboratory testing with high quality standard in Indonesia. • Support Health Tourism de
Slide 31: 1H2022 Revenue (Unaudited)
1H2022 Revenue (Unaudited) Revenue Quarterly Revenue in IDR Billion in IDR Billion 2022 2021 2020 • Revenue slowing FY16-FY21 CAGR +14.3% 1H17-1H22 CAGR +9.0% down by -16.3% yoy, 2019 2018 2017 due to healthcare 2016 market normalization 3Q21, and the impact of 752 Holiday and Fasting 2,652 1Q21, 4Q
Slide 32: Financial Update
5 FINANCIAL UPDATE 32
Slide 33: 1H2022 Gross Profit & Net Income (Unaudited)
1H2022 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY16-FY21 CAGR +15.5% 1H17-1H22 CAGR +10.2% FY16-FY21 CAGR +47.8% 1H17-1H22 CAGR +22.2% 1H21-1H22 1H21-1H22 growth -18.2% growth -46.9% 621.6 23.4% 24.3% 61.6% 61.9% 59.7% 60.5% 14.3% 58.7% 12.1% 1
Slide 34: 1H2022 COGS & OPEX (Unaudited)
1H2022 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY21 CAGR +12.5% 1H17-1H22 CAGR +7.5% FY16-FY21 CAGR +5.4% 1H17-1H22 CAGR +5.1% 1H21-1H22 1H21-1H22 1,000 growth -13.1% 878 70 1,019.6 48.6% 827 growth +9.1% 49.0% 770 746 42 65 800 676 713 57.2% 50 827.2 146 47.0% 46 30
Slide 35: 1H2022 Financial Summary (Unaudited)
1H2022 Financial Summary (Unaudited) (in IDR Bn) 1H2022 1H2021 Change (in IDR Bn) 1H2022 1H2021 Change Revenue 1,037.0 1,238.4 -16.3% Total Asset 2,446.8 2,391.8 +2.3% Gross Profit 627.2 766.9 -18.2% Total Equity 2,036.9 1,928.8 +5.6% EBIT 188.8 365.5 -48.4% EBT 201.3 381.2 -47.2% Net Income 159.8 3
Slide 36: Thank You!
THANK YOU! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150 Jakarta 10430, Indonesia www.prodia.co.id 36
PT Prodia Widyahusada — H1 2022 Earnings Presentation on 6ix